ABSTRACT
Fc-dependent effector mechanisms may contribute to antibody-mediated rejection (ABMR), and distinct gene polymorphisms modifying the function of Fc gamma receptors (FcγRs) may influence the capability of donor-specific antibodies (DSAs) to trigger inflammation. To evaluate the relevance of functional FcγR variants in late ABMR, 85 DSA-positive kidney allograft recipients, who were recruited upon antibody screening of 741 prevalent patients, were genotyped for polymorphisms in FcγRIIA (FCGR2A-H/R131 ; rs1801274), FcγRIIIA (FCGR3A-V/F158 ; rs396991), and FcγRIIIB (FCGR3B-neutrophil antigen 1 ([NA1]/NA2; rs35139848). Individuals with high-affinity FCGR3A-V158 alleles (V/V158 or V/F158 ) showed a higher rate (and extent) of peritubular capillaritis (ptc) in protocol biopsies than homozygous carriers of the lower-affinity allele (ptc score ≥1: 53.6% vs 25.9%; P = .018). Associations were independent of C1q-binding to DSA or capillary C4d. In parallel, there was a trend toward increased macrophage- and injury-repair response-associated transcript subsets. Kidney function over 24 months, however, was not different. In support of a functional role of FcγRIIIA polymorphism, NK92 cells expressing FCGR3A-V158 produced >2 times as much interferon gamma upon incubation with HLA antibody-coated cells as those expressing FCGR3A-F158 . FcγRIIA and FcγRIIIB polymorphisms were not associated with allograft morphology. Our data suggest that the presence of high-affinity FcγRIIIA variants may favor DSA-triggered microcirculation inflammation.
Subject(s)
Graft Rejection/diagnosis , Inflammation/diagnosis , Isoantibodies/adverse effects , Kidney Transplantation/adverse effects , Polymorphism, Genetic , Receptors, IgG/genetics , Adult , Cross-Sectional Studies , Female , Follow-Up Studies , GPI-Linked Proteins/genetics , Genotype , Graft Rejection/etiology , Graft Survival , Humans , Inflammation/etiology , Kidney Failure, Chronic/genetics , Kidney Failure, Chronic/surgery , Male , Microcirculation , Middle Aged , Postoperative Complications , Prognosis , Risk Factors , Tissue DonorsABSTRACT
The classical pathway (CP) of complement may contribute to the pathogenesis of antibody-mediated rejection (ABMR). Selective CP blockade may be a promising strategy to counteract rejection. The objective of this first-in-patient phase 1b trial was to evaluate the safety/tolerability and CP-blocking potential of 4 weekly doses (60 mg/kg) of the anti-C1s antibody BIVV009 in complement-mediated disorders. Here we describe the results in a cohort of 10 stable kidney transplant recipients (median of 4.3 years posttransplantation) with late active ABMR and features of CP activation, such as capillary C4d or complement-fixing donor-specific antibodies (DSA). During 7 weeks follow-up, no severe adverse events were reported, and BIVV009 profoundly inhibited overall and DSA-triggered CP activation in serum. Five of 8 C4d-positive recipients turned C4d-negative in 5-week follow-up biopsies, while another 2 recipients showed a substantial decrease in C4d scores. There was, however, no change in microcirculation inflammation, gene expression patterns, DSA levels, or kidney function. In conclusion, we demonstrate that BIVV009 effectively blocks alloantibody-triggered CP activation, even though short-course treatment had no effect on indices of activity in late ABMR. This initial trial provides a valuable basis for future studies designed to clarify the therapeutic value of CP blockade in transplantation. ClinicalTrials.gov NCT#02502903.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Complement C1s/immunology , Graft Rejection/drug therapy , Graft Survival/drug effects , Isoantibodies/adverse effects , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Adult , Aged , Allografts , Complement Activation/immunology , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Rejection/pathology , Graft Survival/immunology , HLA Antigens/immunology , Humans , Kidney Function Tests , Male , Middle Aged , Postoperative Complications , Prognosis , Prospective Studies , Risk Factors , Tissue DonorsABSTRACT
The authors conducted a prospective trial to assess the feasibility of real time central molecular assessment of kidney transplant biopsy samples from 10 North American or European centers. Biopsy samples taken 1 day to 34 years posttransplantation were stabilized in RNAlater, sent via courier overnight at ambient temperature to the central laboratory, and processed (29 h workflow) using microarrays to assess T cell- and antibody-mediated rejection (TCMR and ABMR, respectively). Of 538 biopsy samples submitted, 519 (96%) were sufficient for microarray analysis (average length, 3 mm). Automated reports were generated without knowledge of histology and HLA antibody, with diagnoses assigned based on Molecular Microscope Diagnostic System (MMDx) classifier algorithms and signed out by one observer. Agreement between MMDx and histology (balanced accuracy) was 77% for TCMR, 77% for ABMR, and 76% for no rejection. A classification tree derived to provide automated sign-outs predicted the observer sign-outs with >90% accuracy. In 451 biopsy samples where feedback was obtained, clinicians indicated that MMDx more frequently agreed with clinical judgment (87%) than did histology (80%) (p = 0.0042). In 81% of feedback forms, clinicians reported that MMDx increased confidence in management compared with conventional assessment alone. The authors conclude that real time central molecular assessment is feasible and offers a useful new dimension in biopsy interpretation. ClinicalTrials.gov NCT#01299168.
Subject(s)
Biomarkers/metabolism , Gene Expression Profiling , Graft Rejection/diagnosis , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Adult , Aged , Aged, 80 and over , Biopsy , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Rejection/metabolism , Graft Survival , Humans , Kidney Function Tests , Male , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Young AdultABSTRACT
The classic pathway (CP) of complement is believed to significantly contribute to alloantibody-mediated transplant injury, and targeted complement inhibition is currently considered to be a promising approach for preventing rejection. Here, we investigated the mode of action and efficacy of the humanized anti-C1s monoclonal antibody TNT009 and its parental mouse variant, TNT003, in preclinical in vitro models of HLA antibody-triggered CP activation. In flow cytometric assays, we measured the attachment of C1 subcomponents and C4/C3 split products (C4b/d, C3b/d) to HLA antigen-coated flow beads or HLA-mismatched aortic endothelial cells and splenic lymphocytes. Anti-C1s antibodies profoundly inhibited C3 activation at concentrations >20 µg/mL, in both solid phase and cellular assays. While C4 activation was also prevented, this was not the case for C1 subcomponent attachment. Analysis of serum samples obtained from 68 sensitized transplant candidates revealed that the potency of inhibition was related to the extent of baseline CP activation. This study demonstrates that anti-C1s antibodies TNT009 and TNT003 are highly effective in blocking HLA antibody-triggered complement activation downstream of C1. Our results provide the foundation for clinical studies designed to investigate the potential of TNT009 in the treatment or prevention of complement-mediated tissue injury in sensitized transplant recipients.
Subject(s)
Antibodies, Monoclonal/pharmacology , Complement Activation/immunology , Complement C1s/immunology , Graft Rejection/drug therapy , HLA Antigens/immunology , Isoantibodies/adverse effects , Kidney Transplantation/adverse effects , Animals , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Survival , Humans , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/surgery , Kidney Function Tests , Mice , PrognosisABSTRACT
Histologic assessment of kidney transplant biopsies relies on cortex rather than medulla, but for microarray studies, the proportion cortex in a biopsy is typically unknown and could affect the molecular readings. The present study aimed to develop a molecular estimate of proportion cortex in biopsies and examine its effect on molecular diagnoses. Microarrays from 26 kidney transplant biopsies divided into cortex and medulla components and processed separately showed that many of the most significant differences were in glomerular genes (e.g. NPHS2, NPHS1, CLIC5, PTPRO, PLA2R1, PLCE1, PODXL, and REN). Using NPHS2 (podocin) to estimate proportion cortex, we examined whether proportion cortex influenced molecular assessment in the molecular microscope diagnostic system. In 1190 unselected kidney transplant indication biopsies (Clinicaltrials.govNCT01299168), only 11% had <50% cortex. Molecular scores for antibody-mediated rejection, T cell-mediated rejection, and injury were independent of proportion cortex. Rejection was diagnosed in many biopsies that were mostly or all medulla. Agreement in molecular diagnoses in paired cortex/medulla samples (23/26) was similar to biological replicates (32/37). We conclude that NPHS2 expression can estimate proportion cortex; that proportion cortex has little influence on molecular diagnosis of rejection; and that, although histology cannot assess medulla, rejection does occur in medulla as well as cortex.
Subject(s)
Biomarkers/metabolism , Graft Rejection/diagnosis , Kidney Cortex/pathology , Kidney Medulla/pathology , Kidney Transplantation/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Follow-Up Studies , Gene Expression Profiling , Graft Rejection/etiology , Graft Survival , Humans , Kidney Cortex/injuries , Kidney Cortex/metabolism , Kidney Failure, Chronic/surgery , Kidney Medulla/injuries , Kidney Medulla/metabolism , Male , Middle Aged , Postoperative Complications , Prognosis , Young AdultABSTRACT
BACKGROUND: Selective interleukin-2 receptor (IL2R) blockade is one option to decrease acute rejection rates in kidney transplant recipients. However, there are little data on the impact of basiliximab in a triple immunosuppressive regimen (tacrolimus, mycophenolate mofetil, and low-dose steroids). Thus, this analysis aims at investigating the impact of basiliximab induction on rejection rates and immediate graft function following kidney transplantation. METHODS: Basiliximab was introduced in our center according to our center's policy in the beginning of 2011. Patients who received basiliximab (n = 83) were compared with patients without induction therapy (n = 65) transplanted before the introduction of IL2R antibody induction. RESULTS: The use of basiliximab as induction therapy decreased the incidence of biopsy-proven acute rejection (BPAR) within the 1st year after transplantation (21.5% vs 14.5%; P = .283). Overall rejection episodes (including BPAR and borderline rejection) were significantly reduced in patients with basiliximab compared with patients without (41.5% vs 24.1%; P = .033). However, graft function (incidence of delayed graft function, primary nonfunction, slow graft function, and serum creatinine decline) and overall outcome (patient and graft survivals) were similar in both groups. CONCLUSIONS: We found a favorable impact of basiliximab induction therapy on early acute rejection rate. The impact on long-term outcome must be addressed in further randomized controlled trials.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Immunotherapy , Kidney Failure, Chronic/surgery , Kidney Transplantation , Recombinant Fusion Proteins/therapeutic use , Adult , Aged , Basiliximab , Female , Graft Survival , Humans , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Retrospective Studies , Steroids/therapeutic use , Tacrolimus/therapeutic useABSTRACT
BACKGROUND: Live kidney donation represents the gold standard for renal replacement therapy. Due to ABO and HLA incompatibility between donor and recipient pairs, one third of possible transplantations cannot be performed. Kidney exchange programs in combination with extracorporeal desensitization have been introduced to enable successful kidney transplantation in such circumstances. OBJECTIVE: This review discusses the current indications, methods, ethical problems and results within such programs. MATERIALS AND METHODS: Relevant Medline articles were analyzed and personal experiences of the authors are included in this article. RESULTS: Kidney exchange programs in combination with extracorporeal desensitization enable successful transplantation for most patients. DISCUSSION: The best combinations of existing strategies have to be defined and newly arisen ethical questions have to be answered.
Subject(s)
Desensitization, Immunologic/methods , Graft Enhancement, Immunologic/methods , Kidney Failure, Chronic/surgery , Kidney Transplantation/methods , Tissue and Organ Procurement/methods , ABO Blood-Group System , Blood Group Incompatibility/immunology , Blood Group Incompatibility/therapy , Graft Rejection/immunology , Graft Rejection/prevention & control , HLA Antigens , Humans , Immunosorbent Techniques , Immunosuppression Therapy/methods , Kidney Failure, Chronic/immunology , Living Donors , Plasmapheresis/methodsABSTRACT
The impact of vesicoureteral reflux (VUR) on renal allograft outcomes is debatable, with small cohort studies reporting controversial results. The objective of this retrospective study was to evaluate long-term clinical effects of early VUR in a large cohort of kidney transplant patients. Posttransplantation voiding cystourethrography was used to evaluate 646 consecutive kidney transplant recipients before discharge. The study endpoints included VUR grade, death-censored graft or patient survival, renal function, proteinuria and occurrence of urinary tract infections (UTIs). Of the 646 recipients, 263 (40.7%) were diagnosed with VUR. VUR grade II was most common (19.8%), followed by grades III (10.2%), I (7.9%) and IV (2.8%). VUR was less common in transplantations performed by experienced compared to inexperienced surgeons (36% vs. 48%; p = 0.004). VUR did not affect death-censored graft or patient survival and was not associated with proteinuria or occurrence of UTIs. Patients with VUR had a lower eGFR at 1 year after transplantation than did patients without VUR (60 vs. 52 mL/min/1.73 m(2) ; p = 0.02), although this difference was not observed at 3 and 5 years after transplantation. We conclude that early VUR, a common finding among renal transplant patients, may not have a meaningful impact on long-term transplant outcomes.
Subject(s)
Kidney Transplantation , Urination , Urography/methods , Vesico-Ureteral Reflux/complications , Adult , Female , Humans , Kidney Transplantation/adverse effects , Male , Middle Aged , Proteinuria/etiology , Proteinuria/prevention & control , Urinary Tract Infections/etiology , Urinary Tract Infections/prevention & controlABSTRACT
Recipient allosensitization represents a major barrier to transplantation. Sensitized patients awaiting a deceased donor kidney transplant often face unacceptably long waiting times and are more prone to rejection, even in the absence of a positive crossmatch (XM). Two major strategies have been shown to facilitate the access to transplantation: specific allocation programs designed to enhance the availability of a well-matched allograft; and recipient desensitization to decrease levels of humoral alloreactivity. Over the last two to three decades, a variety of desensitization strategies have been published. Such protocols are based on the use of apheresis for direct alloantibody removal from the circulation, or high dose intravenous immunoglobulin and/or CD20 antibody rituximab for modulation of B cell immunity. An attractive approach may be the application of apheresis for rapid desensitization, with or without XM conversion, immediately before transplantation, a particular challenge because of the short interval between the transplant offer and surgery. It was shown that with currently available treatment strategies many high risk patients can be successfully transplanted within an acceptable time period. However, there is still a need for further improvement, as rejection and graft loss rates may be considerably higher than those documented for non-sensitized patients. Future studies will have to establish more precise diagnostic criteria to optimize treatment allocation and monitoring. Moreover, systematic trials are needed to assess the efficiency of innovative treatment concepts, such as the use of agents that directly affect alloantibody-producing plasma cells.
Subject(s)
Desensitization, Immunologic , Kidney Transplantation/immunology , Humans , Preoperative Care , Tissue Donors , Waiting ListsABSTRACT
Various desensitization protocols were shown to enable successful living donor kidney transplantation across a positive complement-dependent cytotoxicity crossmatch (CDCXM). Positive crossmatch transplantation, however, is less well established for deceased donor transplantation. We report a cohort of 68 deceased donor renal allograft recipients who, on the basis of broad sensitization (lymphocytotoxic panel reactivity ≥40%), were subjected to a protocol of peritransplant immunoadsorption (IA). Treatment consisted of a single session of immediate pretransplant IA (protein A) followed by posttransplant IA and antilymphocyte antibody therapy. Twenty-one patients had a positive CDCXM, which could be rendered negative by pretransplant apheresis. Solid phase HLA antibody detection revealed preformed donor-specific antibodies (DSA) in all 21 CDCXM-positive and in 30 CDCXM-negative recipients. At 5 years, overall graft survival, death-censored graft survival and patient survival were 63%, 76% and 87%, respectively, without any differences between CDCXM-positive, CDCXM-negative/DSA-positive and CDCXM-negative/DSA-negative recipients. Furthermore, groups did not differ regarding rates of antibody-mediated rejection (24% vs. 30% vs. 24%, p = 0.84), cellular rejection (14% vs. 23% vs. 18%, p = 0.7) or allograft function (median 5-year serum creatinine: 1.3 vs. 1.8 vs. 1.7 mg/dL, p = 0.62). Our results suggest that peritransplant IA is an effective strategy for rapid desensitization in deceased donor transplantation.
Subject(s)
Blood Grouping and Crossmatching , Desensitization, Immunologic , Immunosorbent Techniques , Kidney Transplantation/immunology , Living Donors , Postoperative Care , Preoperative Care , Adolescent , Adult , Cadaver , Cohort Studies , Female , Graft Rejection/therapy , Humans , Immunosuppression Therapy , Male , Middle Aged , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: Patients with symptomatic peripheral artery disease (PAD) are considered cardiovascular high-risk patients. Our aim was to investigate whether incidental renal artery stenosis (RAS) increases the risk for adverse cardiovascular and renal outcomes in these patients. MATERIALS AND METHODS: We prospectively enrolled 487 consecutive patients admitted for revascularization of symptomatic PAD and performed a renal overview angiogram categorizing RAS as absent (0-29%), moderate (30-59%) and severe (>or= 60%) respectively. Clinical follow-up was for median 15 months (IQR 12-22) for the occurrence of major adverse events [MAE: composite of death, myocardial infarction (MI), stroke, percutaneous coronary intervention, coronary bypass surgery, amputation and kidney failure]. Glomerular filtration rates (GFR) were obtained at 12 months to quantify the course of renal function. RESULTS: A severe RAS was found in 76 patients (15.6%). Overall MAE occurred in 121 patients (24.8%), the composite endpoint of MI, stroke, amputation and death occurred in 101 patients (20.7%). Patients with a severe RAS had a 1.87-fold increased adjusted risk for MAE (95% CI 1.12-3.12, P = 0.017), a 2.51-fold increased adjusted risk for occurrence of the composite endpoint of MI, stroke, amputation and death (95% CI 1.45-4.34, P = 0.001) and a 2.93-fold increased risk for death (95% CI 1.41-6.08, P = 0.004), compared to those of patients without RAS respectively. We observed a significant association between the decrease of GFR over the 12-month follow-up period and the severity of RAS by multivariable analysis (P = 0.044). CONCLUSION: Severe RAS in patients with symptomatic PAD is an independent predictor of major adverse cardiovascular events, adverse renal outcome and mortality.
Subject(s)
Cardiovascular Diseases/mortality , Kidney Failure, Chronic/mortality , Peripheral Vascular Diseases/mortality , Renal Artery Obstruction/mortality , Aged , Angiography , Cardiovascular Diseases/diagnosis , Female , Glomerular Filtration Rate , Humans , Incidence , Kidney Failure, Chronic/complications , Male , Middle Aged , Peripheral Vascular Diseases/complications , Predictive Value of Tests , Prospective Studies , Renal Artery Obstruction/complications , Risk FactorsABSTRACT
AIMS: Elevated calcitonin concentrations in dialysis patients had led to thyroidectomy for a benign C-cell hyperplasia in dozens of patients in the past decade. The prevalence of hypercalcitoninemia, however, has not been examined in a large cohort of dialysis patients. METHODS: We, therefore, measured calcitonin concentrations in 283 dialysis patients. We used different reference intervals: according to the threshold to perform further stimulation tests (i.e. > 10 pg/ml) and new reference intervals for the currently used assay (i.e. serum calcitonin concentration < 11.5 pg/ml in men and < 4.6 pg/ml in women). RESULTS: Median calcitonin concentrations of men and women were 12 (1; 290) pg/ml vs 2 pg/ml (1; 45), respectively, (p < 0.0001). The prevalence of hypercalcitoninemia was 10% in women and 58% in men using a cut-off of 10 pg/ml. Applying the new reference intervals 31% of women and 54% of men presented with hypercalcitoninemia. All patients with basal calcitonin concentrations above 50 pg/ml were men (highest calcitonin concentration was 290 pg/ml). Two of them underwent thyroidectomy and had C-cell hyperplasia. CONCLUSION: The prevalence of hypercalcitoninemia in dialysis patients amounts to 46%. It is more common in male than in female dialysis patients.
Subject(s)
Biomarkers, Tumor/blood , Calcitonin/blood , Carcinoma, Medullary/epidemiology , Kidney Failure, Chronic/therapy , Kidney Transplantation , Renal Dialysis/methods , Thyroid Neoplasms/epidemiology , Austria/epidemiology , Carcinoma, Medullary/blood , Carcinoma, Medullary/etiology , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Luminescent Measurements , Male , Middle Aged , Prevalence , Prognosis , Retrospective Studies , Thyroid Neoplasms/blood , Thyroid Neoplasms/etiology , ThyroidectomyABSTRACT
Chemokines are involved in the recruitment of inflammatory cells to vascularized allografts. The chemokine CCL2/MCP-1 is expressed during allograft dysfunction, which is associated with the recruitment of inflammatory cells. Both intrinsic renal cells (donor origin) as well as infiltrating inflammatory cells (recipient origin) can be a source of CCL2/MCP-1. We previously demonstrated that the recipient MCP-1-2518G polymorphism is associated with increased CCL2/MCP-1 production by inflammatory cells and decreased renal allograft survival. We evaluated the impact of the MCP-1-2518G polymorphism in donor cells on renal allograft outcomes. We enrolled 252 recipients of kidney allografts in this retrospective study who had received grafts from 152 cadaveric donors. The CCL2/MCP-1 genotype was assessed using genomic DNA isolated from cryopreserved donor splenocytes. Outcome parameters studied were acute biopsy proven rejection (Banff criteria), serum creatinine, and glomerular filtration rate (GFR) at 1 year after transplantation, allograft loss, and death. MCP-1-2518 genotypes were in HW equilibrium. A/A was present in 125 (49.6%), A/G in 107 (42.5%), and G/G in 20 (7.9%) donor kidneys. There were no significant differences in the number of rejection episodes, the number of allograft losses, serum creatinine, GFR, or overall survival 1 year after transplantation. In contrast with the detrimental effect of the CCL2/MCP-1 polymorphism of the recipient, the CCL2/MCP-1 polymorphism of the donor has no impact on the allograft outcome during the first year after transplantation. The impact on the long-term outcomes needs further evaluation.
Subject(s)
Chemokine CCL2/genetics , Kidney Transplantation/physiology , Polymorphism, Single Nucleotide , Chemokines/genetics , DNA Primers , Follow-Up Studies , Glomerular Filtration Rate , Humans , Restriction Mapping , Retrospective Studies , Transplantation, Homologous , Treatment OutcomeABSTRACT
Humoral alloreactivity is well established to predict adverse allograft outcomes. However, in some recipients, alloantibodies may also occur in the absence of graft dysfunction. We evaluated if and how often complement- and noncomplement-fixing alloantibodies are detectable in stable recipients and whether, in this context, they affect long-term outcomes. Sera obtained from 164 kidney transplant recipients at 2, 6 and 12 months were evaluated by FlowPRA screening and single-antigen testing for detection of IgG- or C4d-fixing HLA panel reactivity and donor-specific antibodies (DSA). Applying stringent criteria, we selected 34 patients with an uneventful 1-year course (no graft dysfunction or rejection) and excellent graft function at 12 months [estimated glomerular filtration rate (eGFR) >or=60 mL/min and proteinuria Subject(s)
Antibodies/blood
, HLA Antigens/immunology
, Kidney Transplantation/immunology
, Outcome Assessment, Health Care
, Transplantation
, Adult
, Complement C4b
, Female
, Graft Rejection/epidemiology
, Graft Rejection/immunology
, Humans
, Immunoglobulin G/blood
, Incidence
, Longitudinal Studies
, Male
, Middle Aged
, Peptide Fragments/blood
, Predictive Value of Tests
, Retrospective Studies
, Transplantation, Homologous
ABSTRACT
Capillary C4d deposition is a valuable marker of antibody-mediated rejection (AMR). In this analysis, flow cytometric detection of alloantibody-triggered C4d deposition to HLA antigen-coated microparticles ([C4d]FlowPRA) was evaluated for its value as a marker for C4d deposition in renal allografts. For comparative analysis, 105 first renal biopsies performed for graft dysfunction and an equal number of concurrent sera were subjected to immunohistochemistry and [C4d] plus standard [IgG]FlowPRA, respectively. C4d deposition/fixation was detected in 17 biopsies and, applying [C4d]FlowPRA HLA class I and II screening, also in a small number of corresponding sera (N = 20). IgG reactivity detected by standard [IgG]FlowPRA was more frequent (49% of sera). Comparing [C4d]FlowPRA screening with capillary C4d staining, we found a high level of specificity (0.92 [95% confidence interval: 0.86-0.98]), which far exceeded that calculated for [IgG]FlowPRA (0.60 [0.50-0.70]). [IgG]FlowPRA screening, however, turned out to be superior in terms of sensitivity (0.94 [0.83-1.05] vs. 0.76 [0.56-0.97] calculated for C4d-fixing panel reactivity). Remarkably, posttransplant single antigen testing for identification of complement-fixing donor-specific alloreactivities failed to improve the predictive value of FlowPRA-based serology. In conclusion, our results suggest that detection of complement-fixing HLA panel reactivity could provide a specific tool for monitoring of C4d-positive AMR.
Subject(s)
Complement C4b/metabolism , HLA Antigens/immunology , Isoantibodies/analysis , Kidney Transplantation/immunology , Kidney/blood supply , Kidney/metabolism , Peptide Fragments/metabolism , Adult , Capillaries/immunology , Capillaries/metabolism , Complement Fixation Tests , Female , Humans , Isoantibodies/physiology , Kidney/immunology , Male , Middle Aged , Transplantation, HomologousABSTRACT
Accumulation of inflammatory cells within capillaries is a common morphologic feature of humoral renal allograft rejection and is most easily appreciated if it occurs in glomeruli. The aim of our study was to determine the amount and composition of immune cells within glomeruli and peritubular capillaries (PTC) in cellular and humoral allograft rejection. Immunofluorescent double-labeling for CD31 and CD3 or CD68 was used for phenotyping and enumerating immune cells within glomeruli and PTC. The major findings are: (1) accumulation of immune cells in PTC is far more common than it would be anticipated based on the assessment by conventional histology; (2) it is not the absolute number of immune cells accumulating within capillaries, but rather the composition of the intracapillary cell population that distinguishes humoral rejection from cellular rejection and (3) in C4d positive biopsies a predominantly monocytic cell population accumulates not only within glomeruli but also within PTC. The median value of monocyte/T-cell ratio within PTC was 2.3 in C4d positive biopsies but only 1 (p = 0.0008) in C4d negative biopsies. Given their prominent presence within capillaries and their extensive biological versatility monocytes might contribute to the capillary damage observed in acute and chronic allograft rejection.
Subject(s)
Capillaries/pathology , Graft Rejection/pathology , Kidney Glomerulus/blood supply , Kidney Transplantation/immunology , Kidney Tubules/blood supply , Monocytes/pathology , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Biopsy , CD3 Complex/metabolism , Complement C4b/metabolism , Graft Rejection/immunology , Humans , Kidney Transplantation/pathology , Monocytes/immunology , Neutrophils/immunology , Neutrophils/pathology , Peptide Fragments/metabolism , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Retrospective Studies , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Transplantation, Homologous/immunology , Transplantation, Homologous/pathologyABSTRACT
The Division of Transplantation at the Medical University of Vienna, Austria was established by Dr Franz Piza, who performed the first deceased donor kidney transplantation in Vienna in 1965. During the next 43 years, 4,849 transplants were performed at this unit. Data were analysed in the time period 1993-2006 for 2,165 deceased donor transplants (1,734 first and 431 regrafts) and 263 living donor transplants. Long-term follow-up was available for more than 95% of all grafts and all recipients had at least 9 months of follow-up. Two- and 6-year graft survival rates were 81.4% and 66.3%, respectively, for first deceased donor grafts, 76.1% and 61.8% for regrafts and 91.5% and 79.1% for living transplants. Appropriate immunosuppression, HLA matching and crossmatching supported by solid basic scientific research have proved successful in achieving good graft survival at our unit.
Subject(s)
Graft Rejection/mortality , Kidney Failure, Chronic/mortality , Kidney Transplantation/mortality , Adolescent , Adult , Age Distribution , Aged , Austria/epidemiology , Child , Child, Preschool , Graft Rejection/immunology , Graft Survival , HLA Antigens , Humans , Incidence , Infant , Kidney Failure, Chronic/surgery , Living Donors/statistics & numerical data , Middle Aged , Prevalence , Retrospective StudiesABSTRACT
Antibody-mediated rejection (AMR) frequently causes refractory graft dysfunction. This randomized controlled trial was designed to evaluate whether immunoadsorption (IA) is effective in the treatment of severe C4d-positive AMR. Ten out of 756 kidney allograft recipients were included. Patients were randomly assigned to IA with protein A (N = 5) or no such treatment (N = 5) with the option of IA rescue after 3 weeks. Enrolled recipients were subjected to tacrolimus conversion and, if indicated, 'anti-cellular' treatment. All IA-treated patients responded to treatment. One death unrelated to IA occurred after successful reversal of rejection. Four control subjects remained dialysis-dependent. With the exception of one patient who developed graft necrosis, non-responders were subjected to rescue IA, however, without success. Because of a high graft loss rate in the control group the study was terminated after a first interim analysis. Even though limited by small patient numbers, this trial suggests efficiency of IA in reversing severe AMR.
Subject(s)
Complement C4b/analysis , Graft Rejection/prevention & control , Immunotherapy/methods , Kidney Transplantation/adverse effects , Peptide Fragments/analysis , Staphylococcal Protein A/therapeutic use , Adult , Aged , Graft Rejection/immunology , Graft Rejection/therapy , Humans , Middle Aged , Necrosis , Renal Dialysis , Staphylococcal Protein A/administration & dosage , Tacrolimus/therapeutic use , Treatment OutcomeABSTRACT
Recipient presensitization represents a major risk factor for kidney allograft loss. Complement fixation may be a critical attribute of deleterious alloantibodies. We investigated clinical impact of complement-fixing HLA presensitization employing [C4d]FlowPRA, a novel assay permitting selective detection of HLA panel reactive antibody (PRA)-triggered C4 complement split product deposition. A cohort of 338 kidney transplants was evaluated for presensitization applying [C4d]FlowPRA together with [IgG]FlowPRA and complement-dependent cytotoxicity (CDC)-PRA. Analysis of HLA class I alloreactivities revealed a high incidence of C4d-positive graft dysfunction in [IgG]FlowPRA(+)/[C4d]FlowPRA(+) and [IgG]FlowPRA(+)/[C4d]FlowPRA(-) recipients (23% and 22% vs. 3% in [IgG]FlowPRA(-) patients). Only patients with complement-fixing HLA class I immunization had inferior graft survival [75% (3 years) vs. 91% and 89%, respectively (p=0.036)]. Despite frequent finding of capillary C4d deposition (28%), complement-fixing HLA class II immunization was not associated with inferior survival rates. This may have been due to reduction of clinical effects by intense immunosuppression in presensitized patients. Evaluating CDC, 29% of CDC-PRA(+)/[C4d]FlowPRA(+) recipients had C4d-positive graft dysfunction. For these patients 3-year graft survival was worst, followed by CDC-PRA(+)/[C4d]FlowPRA(-) and CDC-PRA(-) patients (76% vs. 81% vs. 90%, p=0.014). Results highlight a strong impact of complement-fixing HLA presensitization. Discerning complement-activating abilities of HLA alloantibodies, [C4d]FlowPRA may help identify recipients at particularly high risk for graft rejection and loss.